Family Medicine Doctors in Saxonburg, PA Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 Danielle J Godinez, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 333 W Main St, Saxonburg, PA 16056 Phone: 724-352-8422 Fax: 724-352-8426 |
 Libro Oniboni, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Alwine Rd, Ste 104, Saxonburg, PA 16056 Phone: 724-352-8840 Fax: 724-352-9033 |
Kathryn Ryan, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Alwine Rd, Suite 104, Saxonburg, PA 16056 Phone: 724-352-8840 Fax: 724-352-9033 |
News Archive
Lack of ARHGAP33 molecule causes neuropsychiatric disorders-related abnormal higher brain functions
A research group led by Osaka University and the University of Tokyo found that the intracellular protein trafficking is important for higher brain functions such as learning and memory. The research group showed that a molecule, ARHGAP33 regulates synaptic functions and behaviors via intracellular protein trafficking and that the lack of ARHGAP33 causes neuropsychiatric disorder-related impaired higher brain functions.
Patients' insurance status affects outcomes of cardiac valve operations in the U.S.
The type of primary insurance patients carry affects outcomes of cardiac valve operations in the United States according to a study in the May issue of the Journal of the American College of Surgeons.
UI chemists debunk misconception about amphotericin
With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.
Finished school – better health for Indigenous Australians
A new report prepared by the Australian Bureau of Statistics (ABS) has found that indigenous Australians who go on to complete their school education fare much better health wise than those who do not.
FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 2 days ago